The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://tiannagaiv601821.wikimidpoint.com/6385751/retatrutide_vs_tirzepatide_a_comparative_analysis